Морфология и патогенез инфаркта миокарда. Эпидемиология и факторы риска, страница 19

50

рис. 3. Сортное лечение ИМ (MB КФК - MB изофермент креа.инфосфокиназь

ЛИТЕРАТУРА

1. Tan LB, Bryant S, Murray RG. 1988. Detrimental haemodynamic effects ofcyclizine in heart failure. Lancet i: 560 - 561.

2. Rentrop KP. 1995. Restoration ofantegrade flow in acute myocardial infarction: the first 15 years. J Am Coil Cardiol 25(No.7, suppi): 15-25.

3. Weaver WD. 1995. Time to thrombolytic treatment: factors affecting delay and their influence on outcome. J Am Coil Cardiol 25(No.7, suppi): 35 — 95.

4. ISIS-2 Collaborative Group. 1988. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17.817 cases of suspected acute myocardial infarction- ISIS-2. Lancet ii: 349-360.

5. Pell AC, Miller HC, Robertson CE, Fox KA. 1992. Effect of'fast track' admission for acute myocardial infarction on delay to thrombolysis. BMJ 304: 83 — 87.

6. LATE Study Group. 1993. Late assessment of thrombolytic therapy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 342: 759 - 766.

7. The GUSTO Investigators. 1993. An international randomised trial comparing four throm- bolytic strategies for acute myocardial infarction. N EngI J Med 329: 673 — 682.

8. Grech ED, Ramsdale DR. 1994. The role of PTCA in acute myocardial infarction. In:

Jackson G (ed.) Difficult Concepts in Cardiology. Martin Duntiz, London, 61 - 72.

9. Grines CL, Browne KF, Marco J et al. 1993. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N EngI J Med 328: 673 - 679.

10. HocmanJS, LeJemtel Т. 1994. Management of cardiogenic shock. In: Julian D, Braunwald E (eds). Management of Acute Myocardial Infarction. WB Saunders. London, 267 — 289.

11. Brand DA, Newcomer LN, Freiburger A, Tian H. 1995. Cardiologists practices com- pared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coil Cardiol 25: 1432 - 1436.

12. ISIS-1 Collaborative Group. 1986. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet ii: 57 - 66.

13. The MIAMI Trial Research Group. 1985. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo controlled international trial. Eur Heart J 6: 199 — 226.

14. Roberts R, Rogers WJ, Mueller HS et al. for the TIM! Investigators. 1991. Immediate versus deferred B-blockade following thrombolytic therapy in patients with acute myo- cardial infarction. (TIMI) 1I-B study. Circulation 83: 422-437.

15. ISIS Collaborative Group. 1995. A randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345: 669 - 685.

16. Yusuf S, Collins R, MacMahon S, Peto R. 1988. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet i:

1088 - 1092.

17. Jackson G. 1995. АСЕ inhibitors after myocardial infarction. BrJ Clin Pract 49: 171.

18. Pfeffer MA, Braunwald E, Moye LA et al. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N EngI J Med 327: 669 - 677.

19. GISS1-3. 1994. Effects of lisinopril and transdermal glyceryl trinitrate singly and to- gether on 6- week mortality and ventricular function after acute myocardial infarction. Lancet 343: 1115-1122.

52

70 Ambriosioni E, Borghi С, Magnani В. 1995. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial inf- arction. N EngI J Med 332: 80 - 85.

21.The Acute Infarction Ramipril Efficacy (A1RE) Study Investigators. 1993. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821 - 328.